Prevention of breast cancer.
With the advent of screening and the increased incidence of breast cancer, concern for the prevention of breast cancer has become forefront in today's society. Determining individual risk is the key to prescribing prevention. Prevention of breast cancer is still under clinical investigation with only one drug, tamoxifen, showing benefit in high risk patients. This paper reviews the possible sites for prevention of neoplastic transformation via biomarkers in a breast cell as well as the investigational drugs and their potential use in the chemoprevention of breast cancer.
Carolin
K A
KA
University of Michigan, 3303 CGC, Ann Arbor 48109-0932, USA.
Pass
H A
HA
D000328:Adult; D000368:Aged; D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D016588:Anticarcinogenic Agents / Q000627:therapeutic use*; D017209:Apoptosis; D001688:Biological Products / Q000494:pharmacology; D001943:Breast Neoplasms / Q000453:epidemiology / Q000235:genetics / Q000473:pathology / Q000517:prevention & control* / Q000601:surgery; D018567:Breast Neoplasms, Male / Q000453:epidemiology; D002338:Carotenoids / Q000627:therapeutic use; D002402:Cathepsin D / Q000235:genetics; D015815:Cell Adhesion Molecules / Q000502:physiology; D002453:Cell Cycle; D017326:Clinical Trials, Phase III as Topic; D004354:Drug Screening Assays, Antitumor; D004968:Estrogens, Non-Steroidal / Q000627:therapeutic use; D005260:Female; D017313:Fenretinide / Q000627:therapeutic use; D020022:Genetic Predisposition to Disease; D006727:Hormone Antagonists / Q000627:therapeutic use; D006801:Humans; D007529:Isoflavones; D008297:Male; D008325:Mammary Neoplasms, Experimental / Q000235:genetics / Q000517:prevention & control; D008408:Mastectomy; D051379:Mice; D008875:Middle Aged; D009389:Neovascularization, Pathologic; D010052:Ovariectomy; D048789:Phytoestrogens; D028321:Plant Preparations; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D051381:Rats; D012176:Retinoids / Q000627:therapeutic use; D018570:Risk Assessment; D012307:Risk Factors; D012643:Selenium / Q000627:therapeutic use; D013629:Tamoxifen / Q000627:therapeutic use; D013729:Terpenes / Q000627:therapeutic use
D000894:Anti-Inflammatory Agents, Non-Steroidal; D016588:Anticarcinogenic Agents; D001688:Biological Products; D015815:Cell Adhesion Molecules; D004968:Estrogens, Non-Steroidal; D006727:Hormone Antagonists; D007529:Isoflavones; D048789:Phytoestrogens; D028321:Plant Preparations; D012176:Retinoids; D013729:Terpenes; D013629:Tamoxifen; D017313:Fenretinide; D002338:Carotenoids; D020849:Raloxifene Hydrochloride; D002402:Cathepsin D; D012643:Selenium